NEW YORK (GenomeWeb) – Researchers at the University of Washington have applied parallel-reaction monitoring (PRM) mass spec to the development of targeted phosphoproteomics assays.

The method, which was detailed in a paper published this week in Nature Methods, leverages PRM's reproducibility and simplicity to generate what the authors, led by UW researcher Judit Villén, described as rapid "plug and play" targeted phosphoprotein assays.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.

Sponsored by

This online, interactive seminar will answer researchers’ most pressing questions about how to gain outstanding research results from proteomic studies.